Another point to note is that it was only Q2 2024 that Resmed had 529,000 patients in their cohort with prescriptions for both GLP-1 medications and positive airway pressure therapy. They're now up to 660,000 patients in their cohort. That's an additional 130,000 patients! I wouldn't brush over this lightly folks.
A few months ago this article below was published. Apologies if this has already been posted, but well worth reading again.
https://www.morningstar.com.au/insights/stocks/248775/resmeds-impressive-earnings
And just as I highlighted, an untapped market awaits imv the wearable technology market.
Tony
GLP-1 and OSA, page-89
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$29.90 |
Change
1.250(4.36%) |
Mkt cap ! $18.94B | |||
| Open | High | Low | Value | Volume |
| $29.38 | $29.90 | $29.28 | $56.93M | 1.920M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2798 | $29.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $29.91 | 9379 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RMD (ASX) Chart |